$FATE
FATE THERAPEUTICS INC
Runway:17 mo
NasdaqMarket cap: —CIK 0001434316
Upcoming catalysts
0 surfacedNo catalysts surfaced for FATE yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07570862 | FT819 | Phase 2 | Not Yet Recruiting | 2029-07-01 |
| NCT06241456 | FT825 | Phase 1 | Recruiting | 2029-05-01 |
| NCT07216105 | FT836 | Phase 1 | Recruiting | 2028-01-01 |
| NCT06308978 | FT819 | Phase 1 | Recruiting | 2027-09-30 |
| NCT05934097 | FT596 | Phase 1 | Withdrawn | 2026-05-01 |
| NCT04629729 | FT819 | Phase 1 | Active Not Recruiting | 2025-06-18 |
| NCT05950334 | FT522 | Phase 1 | Completed | 2025-06-06 |
| NCT05182073 | FT576 (Allogenic CAR NK cells with BCMA expression) | Phase 1 | Completed | 2024-09-20 |
| NCT04023071 | FT516 | Phase 1 | Terminated | 2023-10-23 |
| NCT04245722 | FT596 | Phase 1 | Terminated | 2023-09-27 |
| NCT05395052 | FT536 | Phase 1 | Terminated | 2023-08-11 |
| NCT05069935 | FT538 | Phase 1 | Terminated | 2023-08-11 |
| NCT04106167 | Allogeneic natural killer (NK) cell | — | Terminated | 2023-08-11 |
| NCT04551885 | FT516 | Phase 1 | Terminated | 2023-08-11 |
| NCT04614636 | FT538 | Phase 1 | Terminated | 2023-07-13 |
| NCT03841110 | FT500 | Phase 1 | Completed | 2022-11-15 |
| NCT02743351 | ProTmune | Phase 2 | Completed | 2020-12-04 |
| NCT03319459 | FATE-NK100 | Phase 1 | Completed | 2020-05-29 |
| NCT04093622 | Genetically engineered NK cells | — | Terminated | 2020-04-09 |
| NCT02354417 | Biological: ProHema-CB | Phase 1 | Terminated | 2016-12-01 |